You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A novel prodrug for K+-ATP channel activation in the glaucomatous eye
SBC: RADIKAL THERAPEUTICS, INC. Topic: NEIDESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a revolutionary bifunctional small molecule (R-801) for topical therapy of primary open angle glaucoma (POAG). R-801 is constructed from the covalent fusion of 2 chemical domains, each with demonstrated tissue protective properties: 1) a mito-K+-ATP channel activating moiety derived from the isoform non-selective K+-ATP ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New HILIC Materials for Separating Polar Drugs, Biologics, and Metabolites
SBC: AZYP, LLC Topic: NIGMSDESCRIPTION (provided by applicant): The effective separation and analysis of pharmaceutical compounds and their metabolites is essential to researchers that develop new, more effective, safer, and economical medicines. Novel types of biologically deriveddrug compounds (biologics) are becoming more important and prevalent as they match and sometimes exceed the importance of traditional small synth ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Nanoparticulate Coatings Enhance Ion Detection
SBC: IONWERKS INC Topic: NIGMSDESCRIPTION (provided by applicant): A new thin film approach to increasing the gain and sensitivity of current and future fast particle detectors is hypothesized. An increased ion induced secondary electron yield at the first surface of the detector while retaining high timing accuracy will make such detectors suitable replacement for MCP detectors in biological applications such as electron or ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies
SBC: Mattek Corporation Topic: NIGMSDESCRIPTION (provided by applicant): The perioral route for drug administration remains the most convenient way of clinical therapy and is preferred by patients, however, good bioavailability is a necessary characteristic of new candidate therapeutics. A key parameter for determining oral bioavailability is drug transport and permeability across the small intestine (SI) epithelium. Therefore, in ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury
SBC: AQUILUS PHARMACEUTICALS INC Topic: NIGMSDESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a proprietary matrix metalloproteinase (MMP) inhibitor, AQU-010, for blocking neuropathic pain and morphine tolerance in a thermal injury (TI) rat model.The goals for Phase I are to scale-up the synthesis of AQU-010, determine its oral pharmacokinetics (PK) and target tissue penetration and then ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay
SBC: GLSynthesis Inc. Topic: NIGMSABSTRACT In this project we propose to exploit the recent successful isolation and reconstitution of the important ATP- dependent drug efflux transporter, ABCG2 (BCRP, Breast Cancer Resistance Protein), and combine it with a new transport assay system, the Fluorosome platform, to characterize the interaction of ABCG2 with drugs and drug candidates. The result will provide a useful, novel, highly ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE
SBC: ZATA PHARMACEUTICALS, INC. Topic: NIGMSDESCRIPTION (provided by applicant): There is enormous potential of oligonucleotides (ON) as therapeutics, but the challenge remains how to effectively deliver ON into cells. Currently, there are no effective and reliable ways of delivery. Outer cell membranes resist the cellular uptake of charged ON, and charges-eliminating backbone modifications such as those in peptide nucleic acids (PNA) and m ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Software for Fragment-based Design of Covalent Inhibitors
SBC: ACPHARIS Topic: NIGMSDESCRIPTION (provided by applicant): Covalent drugs represent a significant portion of current pharmaceuticals, with the top 26 having sales of over 30B in the US alone. While in the past target-directed drug discovery projects rarely pursued covalent binders due to safety concerns, the industry is increasingly considering the use of targeted covalent inhibitors (TCIs) that utilize soft reactive ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
GMP Synthesis and Binding Studies of a Molecular Probe to Glycosaminoglycans
SBC: IONIC PHARMACEUTICALS, LLC Topic: NIGMSAbstract Currently, there are no molecular probes that are specifically designed for quantitative imaging of articular cartilage health. In osteoarthritis (OA), the articular cartilage becomes degraded with loss of glycosaminoglycans (GAGs) from the cartilage matrix serving as an early biomarker of the disease process. As such, there are clinical opportunities to mitigate cartilage damage in patie ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Kidney Progenitor Cells in Regenerative Medicine
SBC: PROBETEX INC Topic: NIGMSProject Summary: We have shown that rat and mouse metanephric mesenchyme (MM) and ureteric bud (UB) cells undergo reciprocal induction to form differentiated tubular epithelium and undergo vasculogenesis forming capillary-like structures in 3-dimensional culture. Because these kidney progenitor cell lines retain differentiation potential, they have enormous potential in state-of-the art areas of r ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health